News
Merck pummelled as MS hope evobrutinib dies in phase 3
Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling th
